Kala Pharmaceuticals Appoints Mark Iwicki As Executive Chairman
WALTHAM, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (Kala), a developer of innovative ophthalmic products based on its proprietary mucus-penetrating particle (MPP) technology, today announced the appointment of Mark Iwicki as Executive Chairman and a member of its board of directors. Mr. Iwicki will help guide corporate strategy and commercial preparations for Kala’s lead product candidate, KPI-121, a novel nanoparticle formulation of loteprednol etabonate in development for the treatment of post-surgical ocular inflammation and pain and for dry eye and meibomian gland disease.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.